A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Malaria, Falciparum Clinical Trial

Official title:

A Phase 1, Randomised, Double Blind Placebo-controlled, First Time in Human Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Oral Doses and Food Effect of GSK4024484 in Healthy Adult Participants.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06171113
• Other study ID #: 218708
• Status: Recruiting
• Phase: Phase 1
• Start date: December 12, 2023
• Est. completion date: August 14, 2025

Study information

• Verified date: February 2024
• Source: GlaxoSmithKline
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 144
• Est. completion date: August 14, 2025
• Est. primary completion date: August 14, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent.

2. Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment.

3. A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, or outside the normal reference range for the population being studied, may be included only if the Investigator considers, that the finding is unlikely to introduce additional risk factors for the participant and will not interfere with the study procedures or endpoints.

4. ALT (Alanine transaminase) and AST (Aspartate transaminase) within the normal range at screening.

5. Total bilirubin within the normal range unless the participant is known to have Gilbert's syndrome.

6. Body weight =50kg, and BMI within the range 19 to 32 kilogram per square metre (kg/m^2) inclusive.

7. Male participants and female participants who are not of child bearing potential.

8. The participant is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria:

1. History or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data in the opinion of the investigator.

2. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

3. An average weekly alcohol intake of >14 units a week within 6 months prior to the study. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.

4. QTcF (Fridericia's formula) >450 msec based on average of triplicate ECGs. The QTcF is the QT interval corrected for heart rate according to QTcF.

5. More than 100 ventricular ectopic complexes in 24 hrs by Holter screening or any other clinically significant Holter abnormalities determined by the investigator.

6. Presence or history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.

7. Heart rate <40 or >100 beats per minute (bpm).

8. Evidence of previous myocardial infarction or any clinically significant conduction abnormality such as (including but not specific to left complete bundle branch block, AV block [2nd degree or higher], WPW syndrome). Long standing RBBB is permitted.

9. Past or intended use of over-the-counter or prescription medication, including herbal medications, CBD-based products, PPIs or H2 antagonists within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longest) prior to dosing. Other concomitant medication may be considered on a case by case basis by the investigator in consultation with the medical monitor. Paracetamol is permitted (capped at =2 grams/day).

10. Participation in the study that would result in loss of blood or blood products in excess of 500 mL within a 56-day period.

11. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.

12. Current enrolment or past participation (within the last 30 days before planned first dose in this study) in any other clinical study involving an investigational study intervention or any other type of medical research.

13. Participants previously dosed in this study.

14. Presence of HBsAg [or HBcAb] at screening or within 3 months prior to first dose of study intervention.

15. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.

16. Positive hepatitis C RNA (ribonucleic acid) test result at screening or within 3 months prior to first dose of study intervention.

17. Positive pre-study drug/alcohol screen.

18. Positive HIV antibody test.

19. Carbon monoxide levels indicative of smoking or more than 10 pack year history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.

20. Use of known recreational drugs or drugs of abuse.

21. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study.

22. A positive confirmation of COVID-19 infection according to local procedures.

Related Conditions & MeSH terms

• Malaria, Falciparum

Intervention

Drug:
• GSK4024484C
Doses administrated orally with 240 mL of water.
• Placebo
Doses administrated orally with 240 mL of water.

Locations

Country	Name	City	State
United Kingdom	Clinical Unit Cambridge (Cuc)-Cambridge-United Kingdom-C	Cambridge

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	Medicines for Malaria Venture

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants reporting serious adverse events (SAEs) after single ascending doses	An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or an abnormal partner pregnancy outcome.	From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)
Primary	Percentage of participants reporting SAEs by severity after single ascending doses	Mild SAE = a type of adverse event (AE) that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate SAE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe SAE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.	From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)
Primary	Percentage of participants reporting SAEs after multiple ascending doses	An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or an abnormal partner pregnancy outcome.	From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)
Primary	Percentage of participants reporting SAEs by severity after multiple ascending doses	Mild SAE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate SAE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe SAE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.	From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)
Primary	Percentage of participants reporting non-serious AEs after single ascending doses	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.	From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)
Primary	Percentage of participants reporting non-serious AEs by severity after single ascending doses	Mild AE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate AE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe AE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.	From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)
Primary	Percentage of participants reporting non-serious AEs after multiple ascending doses	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.	From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)
Primary	Percentage of participants reporting non-serious AEs by severity after multiple ascending doses	Mild AE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate AE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe AE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.	From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)
Secondary	Part A: Area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)] of GSK4024484C following single ascending doses in fasting conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Area under the plasma drug concentration versus time curve from zero (pre-dose) extrapolated to infinite time [AUC(0-8)] of GSK4024484C following single ascending doses in fasting conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Maximum observed plasma drug concentration (Cmax) of GSK4024484C following single ascending doses in fasting conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Time to maximum observed plasma drug concentration (Tmax) of GSK4024484C following single ascending doses in fasting conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Apparent terminal half-life (t1/2) of GSK4024484C following single ascending doses in fasting conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part B: AUC(0-t) of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: AUC(0-8) of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: Cmax of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: Tmax of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: t1/2 of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: Area under the plasma drug concentration versus time curve from zero to time of trough plasma concentration [AUC(0-tau)] of GSK4024484C following multiple ascending doses in fasting conditions		Part B: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part B: Trough plasma concentration (Ctau) of GSK4024484C following multiple ascending doses in fasting conditions		From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Secondary	Part A: AUC(0-t) of GSK4024484C following single ascending doses in fed conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: AUC(0-8) of GSK4024484C following single ascending doses in fed conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Cmax of GSK4024484C following single ascending doses in fed conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: Tmax of GSK4024484C following single ascending doses in fed conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part A: t1/2 of GSK4024484C following single ascending doses in fed conditions		From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Secondary	Part B: Observed accumulation ratio (R) of GSK4024484 based on AUC(Ro) following multiple ascending doses		At Day 1 and at Day 3
Secondary	Part B: Observed accumulation ratio (R) of GSK4024484 based on Cmax(RCmax) following multiple ascending doses		At Day 1 and at Day 3